Phase 4 N=350 Deep Neuromuscular Block for Laparoscopic Surgery
Laparoscopy · Anesthesia Recovery Period
Primary: Percentage of Patients Recovered Cognitively at 1 Week — 91.8; 92.9 percentage of patients recovered
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa
HIV · Impaired Cognition
Primary: Cognitive Function, Global Cognitive Score (Z-score) — 0.15; 0.19; 0.16; 0.25 z score — p=0.68
N/A N=71 Myocardial Lipid and Creatine of Heart Failure on MRS
Myocardial Lipid
Primary: Myocaridal Lipid on MRS — 1.72; 1.18; 1.53; 0.93 ratios
Phase 3 N=110 Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
Severe Hemophilia A
Primary: Immunogenicity of Human-cl rhFVIII: Incidence of Inhibitors — 17; 11; 28 Participants
Phase 1 N=30 A Study of LY2940680 in Healthy Participants
Healthy Participants
Primary: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs — 2; 3; 4; 6 Participants
Phase 1 N=17 A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
Wheezing · Reactive Airway Disease · Mild Asthma
Primary: AUClast of Plasma Budesonide (VR647 Inhalation Suspension Delivered by the VR647 Inhalation System or Pulmicort Respules Delivered by a Conventional Jet Nebulizer)…
N/A N=38 Effects of Inspiratory Muscle Training in Patients With Bronchiectasis
Bronchiectasis
Primary: Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) at 8 Weeks — 60; 71; 84; 69 cmH2O — p=0.005
N/A N=446 PCORI-1502-27462 Navigating High Risk Surgery: Empowering Older Adults to Ask Questions That Inform Decisions About Surgical Treatment
Communication
Primary: Patient Engagement in Decision Making Measured by Clinic Visit Transcript Coding for Number of and Types of Questions Raised — 68; 55; 95; 89 Participants — p=0.353
N/A N=2,019,461 PECARN Emergency Care Registry
Pediatric Emergency Care
Primary: The Number of Visits Obtained From Electronic Health Record Data From the Sites — 421622; 409967; 196300; 376517 number of visits
Early Phase 1 N=25 MEG Study of Acute STX209 Effects in ASD
Autism Disorder
Primary: M50 Latency (Left Hemisphere) — 90.9; 87.4; 89.3 ms
Phase 3 N=105 Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives
Hypertension
Primary: Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) — -8.0; -9.8 mmHg — p=0.024
N/A N=70 Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma
Asthma
Primary: Hydrogen Sulphide in Exhaled Breath — 5.0; 3.2; 4.9 parts per billion — p=>0.05
N/A N=68 Anesthetic Depth and the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery
Strabismus
Primary: the Pediatric Anesthesia Emergence Delirium (PAED) Score — 12.5; 11.4; 6.5; 5.4 score on a scale
Phase 1 N=234 A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects
Healthy
Primary: Observed Sensitization — 0; 0; 0 Participants with Observed Sensitization
Phase 4 N=160 A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants Making at Least One Critical Error After Reading the Patient Information Leaflets (PIL) — 9; 75; 9; 73 Percentage of participants — p=<0.001